Kite Pharma

Kite Pharma, Inc., founded in 2009, is a biomedical engineering company with a core mission to develop innovative cancer immunotherapy products. The company's vision is to restore and enhance the patient's immune system to recognize and eradicate tumors effectively. Kite Pharma specializes in designing and manufacturing personalized cancer treatments, particularly focusing on chimeric antigen receptor (CAR) T-cell therapies. Their market focus is on providing advanced therapeutic solutions for patients with various types of cancer.

Notable figures associated with Kite Pharma include Arie Belldegrun, a renowned oncologist and the company's founder. The company has attracted significant investment from prominent venture capital firms and was acquired by Gilead Sciences in 2017 for $11.9 billion, highlighting its substantial impact and potential in the biopharmaceutical industry. Kite Pharma's key achievements include the FDA approval of Yescarta, a groundbreaking CAR T-cell therapy for certain types of lymphoma, marking a significant advancement in cancer treatment and solidifying its role as a leader in immunotherapy.